IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma
The aim of study is to prove IGEV regimen followed by autologous stem cell transplantation as salvage treatment in patients with refractory or relapsed Hodgkin lymphoma is effective.
Hodgkin Lymphoma
DRUG: IGEV
Complete response rate, 6 weeks
Overall response rate, 6 weeks|3-year progression-free survival rate, 3 years|3-year overall survival rate, 3 years
The standard treatment in patients with refractory or relapsed Hodgkin lymphoma is salvage chemotherapy followed by autologous transplantation for responsive patients. However, the standard of salvage chemotherapy remains uncertain. This study is to evaluate the efficacy and safety of IGEV regimen in a single-center basis.